Meet the Dirt Cheap 6.4%-Yielding Dividend Stock That's Beating the Market in 2026

Altria (MO) has delivered 24% total returns since early 2026, outperforming the S&P 500’s ~14%, but shares pulled back from as high as $77.06 to the mid-$60s amid renewed doubts about sustaining earnings growth. In Q2 2026, Altria reported $5.35B net revenue (ex-excise taxes) with only 1.2% net revenue growth, while GAAP EPS of $1.37 fell 2.8% and missed analyst estimates. The stock still screens inexpensive at ~12x forward earnings with a 6.4% forward dividend yield, but the article flags long-term “value-and-yield trap” risk if cigarette-price tailwinds and smokeless momentum fade.

Analysis

MO is increasingly behaving like a financed yield instrument rather than a growth equity: the market is paying for current cash returns while discounting a shrinking reinvestment runway. That creates asymmetric downside on any earnings wobble, because the holder base is dominated by income screens that can re-rate quickly if coverage or dividend growth credibility slips. In practice, this means the stock can look cheap on forward earnings and still be expensive on long-duration cash-flow durability.

The better second-order winner is PM, which has optionality from category leadership and can absorb volatility through scale while smaller peers fight for shelf space and manufacturing utilization. A contract-manufacturing setup is bullish mainly because it monetizes idle capacity and strengthens the ecosystem around the dominant pouch brand, not because it meaningfully rescues MO’s structural mix problem. Over 1-3 months, the key signal is scanner/share data in oral nicotine; if MO keeps lagging there, the gap versus PM should widen.

Contrarianly, the bear case may be a bit crowded: the dividend floor and low multiple can keep MO supported if rates fall or defensives regain sponsorship. But the real catalyst path is 6-18 months, not days — the question is whether price hikes can still offset volume erosion without accelerating substitution. If that balance breaks, the market will stop treating the payout as secure and start discounting it as a melting-ice-cube cash stream.

Key Decisions for Investors

• Enter a relative-value long PM / short MO pair on weakness over the next 1-3 weeks; target 8-12% relative outperformance if pouch-share and mix trends continue to diverge. Falsifier: MO shows sustained share stabilization or PM growth decelerates materially in next scan data.
• Avoid initiating an outright short MO here; use the stock as a watchlist candidate for a hedgeable income-trap fade rather than a high-conviction bearish single-name. The yield can support price in the near term, especially if Treasury yields drift lower.
• If you must express the bearish view, buy 3-6 month MO put spreads rather than shorting common, with strikes centered around a break below the recent post-rally base. This caps carry risk from the dividend while preserving downside if the market starts pricing lower terminal EPS.
• Add PM on any pullback ahead of the next quarterly update if oral nicotine share data remains favorable; the risk/reward is better than MO because the upside is tied to category leadership, not just payout support.
• Set an alert on MO earnings coverage and dividend-growth commentary: if management signals slowing EPS growth or a smaller future raise, expect a fast multiple reset; if rates fall sharply, cover bearish exposure because the stock may revert to a bond-proxy trade.